A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington's Disease

Administered By

Awarded By

Contributors

Start/End

  • August 6, 2020 - December 31, 2020